Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
15 Maio 2024 - 9:00AM
Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of rare diseases, today
launched a groundbreaking initiative in honor of Prader-Willi
Syndrome (PWS) Awareness Day. The campaign aims to raise awareness
of PWS and celebrate individuals living with this life-threatening
disease.
PWS is a rare and complex genetic
disease affecting approximately one in every 15,000 births
globally. Among its characteristics in infants are hypotonia (weak
muscles), low muscle mass, and weak suck at birth. As the child
develops, the hallmark symptom of potentially life-threatening
hyperphagia (insatiable hunger) becomes evident, which can lead to
early onset morbid obesity. Other characteristic features of PWS
include significant behavioral problems, incomplete sexual
development, growth hormone deficiency, and intellectual
disability. There is elevated mortality in PWS at all ages.
Soleno’s PWS Awareness Month campaign
includes a vibrant billboard in New York Times Square featuring
nearly 100 individuals from the PWS community, who, along with
Soleno Therapeutics, invite others to learn more about PWS and
share words of hope, encouragement, and kindness. Through a new
website at www.Support4PWS.com, the company seeks to foster greater
understanding and support for the PWS community.
"At Soleno, we are deeply committed to
making a meaningful difference in the lives of individuals with
Prader-Willi syndrome,” said Dr. Anish Bhatnagar, Chief Executive
Officer of Soleno Therapeutics. “This campaign aims to highlight
the resilience and beauty within the PWS community, and we hope it
will inspire greater awareness, understanding, and support for
those living with this rare disease."
May is recognized as Prader-Willi
Syndrome Awareness Month, supported annually by organizations such
as the International Prader-Willi Syndrome Organization (IPWSO),
the Foundation for Prader-Willi Research (FPWR) and the
Prader-Willi Syndrome Association USA (PWSA USA), and many more
organizations around the world. In the United States, May 15th has
been designated National Prader-Willi Syndrome Awareness Day,
thanks to a joint resolution by United States Congressman Paul D.
Tonko (D-NY) and Congresswoman Maria Elvira Salazar (R-FL) in
2023.
To learn more about Soleno
Therapeutics' commitment to the PWS community and how you can get
involved in the campaign, visit www.Support4PWS.com.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of
novel therapeutics for the treatment of rare diseases. The
Company’s lead candidate, DCCR (diazoxide choline) extended-release
tablets, a once-daily oral tablet for the treatment of Prader-Willi
syndrome (PWS), recently completed its Phase 3 development program
to support a planned NDA submission.
Corporate Contact:Brian RitchieLifeSci
Advisors, LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Soleno Therapeutics (NASDAQ:SLNO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024